Given the high recurrence rate among IDH mutant gliomas with TP53 mutations, efforts are required to prevent progression to high grade gliomas or secondary glioblastomas, which are difficult to control with multidisciplinary treatments. The gene discussed is IDH1; the disease is central nervous system cancer.